Track Categories
The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
This foundational
session offers a comprehensive examination of cancer as a
multifaceted biological disease. It will cover the cellular, genetic, and
environmental factors contributing to oncogenesis
and tumour progression. Speakers will address advances in molecular profiling
and the impact of these findings on diagnosis and patient-specific treatment
strategies.
Subtracks:
- Cancer Pathogenesis & Molecular Pathways
- Tumour Microenvironment and Signalling
- Novel Cancer Biomarkers
- Epidemiology and Prevention Strategies
- Patient-Centred Cancer Care
- Advances in Cancer Screening Methods
Discussions will
include emerging global trends in cancer incidence and preventive oncology initiatives.
Attendees will gain a holistic understanding of cancer's biological complexity
and its implications for research and clinical care.
This session
highlights recent advances in systemic cancer treatments,
including novel chemotherapy
protocols and combination regimens. It will feature insights into overcoming
multidrug resistance and enhancing treatment efficacy with targeted delivery
technologies.
Experts will present
breakthroughs in nanocarrier systems, liposomal formulations, and localised
intratumoral therapies. Emphasis will be placed on reducing toxicity and
improving patient tolerability while maximising therapeutic outcomes. Case
studies and clinical trial updates will support evidence-based discussions.
Subtracks:
- Advances in Chemotherapy Regimens
- Nanoparticle and Liposome-Based Delivery
- Overcoming Multidrug Resistance
- Pharmacokinetics & Pharmacodynamics in Oncology
- Intratumoral Drug Delivery Techniques
- Chemotherapy-Induced Toxicity Management
Dedicated to the
dynamic field of cancer
immunotherapy, this session will explore immune checkpoint blockade, cellular
therapies, and tumour microenvironment modulation. Experts will address the
latest mechanisms of immune escape and resistance, along with biomarkers for
therapy response prediction.
The session will
spotlight novel combination strategies aimed at enhancing anti-tumour
immunity and patient survival outcomes. Presentations will include updates on
clinical trials, translational research, and regulatory perspectives.
Interactive discussions will focus on challenges in integrating immunotherapy
into clinical practice.
Subtracks:
- Immune Checkpoint Blockade
- Tumour-Infiltrating Lymphocyte Therapy
- CAR-T and CAR-NK Therapies
- Immunotherapy Combination Strategies
- Immune-Related Adverse Events Management
- Cancer Vaccine Development
This session provides
a focused exploration of advancements in breast cancer
screening, diagnostics, and targeted therapies. It will discuss molecular
classification, genetic risk assessment, and subtype-specific treatment
protocols. Special attention will be given to innovations in imaging,
reconstructive surgery, and novel systemic treatments like CDK4/6 inhibitors.
Experts will examine patient-centred approaches, survivorship care, and quality
of life considerations. Recent clinical trial outcomes and evolving global
trends will also be reviewed.
Subtracks:
- Triple-Negative Breast Cancer Advances
- HER2-Targeted Therapies
- Breast Imaging Innovations
- Genetic Risk Assessment & BRCA Mutation Studies
- Breast-Conserving and Reconstructive Surgery
- Survivorship and Quality of Life
This session delves
into the complexities of diagnosing and managing central nervous system
(CNS) tumours. Discussions will cover advancements in imaging modalities,
surgical innovations, and molecular classification of primary and metastatic brain tumours.
Experts will address
unique challenges in treating high-grade gliomas, paediatric brain tumours,
and CNS
metastases. The role of immunotherapy and novel drug delivery systems in
overcoming the blood-brain barrier will be explored. Multidisciplinary care
models and clinical trial data will inform evidence-based practice discussions.
Subtracks:
- Glioma Biology and Treatment
- Innovations in Neuroimaging
- Blood-Brain Barrier Disruption Techniques
- Paediatric Brain Tumour Management
- CNS Metastasis Therapeutics
- Neuro-Oncology Surgery
This session
highlights the essential role of radiology in cancer detection, staging,
treatment planning, and response assessment. Experts will present advances in
imaging technologies, including AI-enhanced radiomics, theranostics, and
molecular imaging.
Discussions will
focus on improving diagnostic accuracy, reducing invasive procedures, and
integrating imaging biomarkers into personalised oncology
care. Emerging trends in image-guided interventions and AI-powered predictive
analytics will be explored. The session aims to redefine imaging as a
therapeutic tool alongside its diagnostic function.
Subtracks:
- PET, MRI, and CT in Oncology
- AI-Driven Cancer Imaging
- Theranostics and Radiopharmaceuticals
- Radiomics and Imaging Biomarkers
- Image-Guided Tumour Ablation
- Molecular Imaging in Cancer Detection
This session offers
an in-depth examination of modern surgical techniques in cancer
treatment, focusing on minimally invasive, robotic-assisted, and reconstructive
surgeries.
Experts will discuss perioperative management, tumour staging, and
strategies for improving oncological
and functional outcomes.
Subtracks:
- Robotic and Minimally Invasive Cancer Surgery
- Sentinel Node Maapping and Tumour Staging
- Oncoplastic and Reconstructive Techniques
- Surgery in Rare and Complex Tumours
- Multidisciplinary Surgical Planning
- Postoperative Recovery and Quality of Life
Emphasis will be
placed on multidisciplinary tumour boards and integrating
surgery with chemotherapy
and radiotherapy. Innovations in tumour localisation, intraoperative imaging,
and postoperative recovery protocols will also be covered. Case-based
discussions will illustrate evidence-based surgical decision-making.
Focusing on
cutting-edge genetic and
cellular approaches, this session will explore gene editing, adoptive cell
transfer, and stem cell-based cancer therapies. Experts
will discuss the application of CRISPR-Cas9, viral vectors,
and non-viral systems for tumour-specific gene
modifications.
Clinical updates on
CAR-T and CAR-NK therapies will be presented, along with strategies to overcome
immune evasion and tumour heterogeneity. Ethical and regulatory frameworks for gene and
cell therapies will also be addressed. Real-world patient experiences and trial
data will underpin discussions.
Subtracks:
- CRISPR, TALEN, and Gene Editing in Oncology
- Viral and Non-Viral Gene Delivery Systems
- CAR-T and CAR-NK Cell Therapy Advances
- Stem Cell-Based Therapeutics
- Regulatory and Ethical Considerations
- Overcoming Immune Escape in Solid Tumours
This session explores
immunotherapy
innovations and therapeutic cancer
vaccines as transformative strategies in oncology.
Topics will include checkpoint inhibitors, adoptive T-cell therapies,
tumour-specific vaccines, and immune modulators.
Experts will examine
mechanisms of immune resistance and biomarker-driven personalisation of immunotherapies. Combination
strategies to enhance efficacy and overcome limitations of monotherapies will
be highlighted.
Subtracks:
- Checkpoint Inhibitor Therapy Developments
- Therapeutic Cancer Vaccines
- Biomarkers for Immunotherapy Response
- Combination Immunotherapy Strategies
- Immune Escape and Resistance Mechanisms
- T-cell Based Adoptive Immunotherapies
This session focuses
on the clinical management and molecular underpinnings of haematologic malignancies
including leukaemia, lymphoma, and multiple myeloma. Discussions will cover
diagnostic innovations, risk stratification, and evolving therapeutic
strategies, such as targeted agents and immunotherapies.
Case studies will
illustrate management of minimal residual disease and treatment-resistant
cases. Stem cell
transplantation and cellular therapies will be explored as curative options in
specific settings. The session will review recent guidelines and clinical trial
outcomes.
Subtracks:
- Acute and Chronic Leukaemia Management
- Lymphoma Therapeutic Strategies
- Multiple Myeloma Updates
- Minimal Residual Disease Monitoring
- Cellular Therapies in Haematologic Cancers
- Stem Cell Transplantation Innovations
This session examines
the complex biological mechanisms driving cancer
metastasis, from tumour cell invasion to colonisation of distant organs.
Discussions will focus on epithelial-mesenchymal transition (EMT),
angiogenesis, and interactions within the tumour
microenvironment that facilitate metastasis.
Experts will present
new insights into circulating tumour cells (CTCs) and exosome-mediated signalling. Innovative
therapeutic targets aimed at halting metastasis progression will also be
explored. Attendees will gain a deeper understanding of why metastasis remains
the leading cause of cancer mortality.
Subtracks:
- Epithelial-Mesenchymal Transition and Metastasis
- Circulating Tumour Cells and Liquid Biopsy
- Tumour Angiogenesis in Metastatic Spread
- Organ-Specific Metastatic Mechanisms
- Exosomes and Metastatic Niche Formation
- Anti-Metastatic Drug Targets
This session
highlights precision oncology’s growing role
through targeted therapies that address specific genetic
mutations and cellular pathways. Experts will discuss the latest approved
targeted agents and ongoing clinical trials investigating kinase inhibitors,
PARP inhibitors, and angiogenesis blockers.
Emphasis will be
placed on resistance mechanisms and strategies to overcome them using
combination therapies. Molecular diagnostics and companion testing will also be
featured. Attendees will discover how these therapies are reshaping cancer care
paradigms.
Subtracks:
- Tyrosine Kinase Inhibitors in Solid and Haematologic Tumours
- PARP Inhibitors in BRCA-Associated Cancers
- Anti-Angiogenic Therapy
- Mechanisms of Drug Resistance and Overcoming Strategies
- Companion Diagnostics in Targeted Therapy
- Emerging Targets in Rare and Aggressive Cancers
A visionary session
spotlighting pioneering research directions and transformative breakthroughs in
oncology.
Experts will present studies on tumour
genomics, novel biomarkers, and therapeutic resistance pathways.
Discussions will also
cover liquid biopsies,
organoid models, and tumour
heterogeneity. The future of precision oncology,
AI-driven analytics, and integrative medicine will be explored. This session
aims to inspire collaborations that bridge basic research and clinical
application.
Subtracks:
- Liquid Biopsy and Circulating Biomarkers
- Tumour Organoids and Preclinical Models
- Novel Therapeutic Resistance Pathways
- AI and Bioinformatics in Oncology Research
- Cancer Epigenetics and Non-Coding RNAs
- Emerging Molecular Targets
This session covers
the diagnosis and management of haematologic malignancies and disorders affecting the lymphatic system. Topics will include bleeding and clotting disorders in cancer patients, lymphomas, and rare haematologic neoplasms.
Discussions will explore
advances in molecular diagnostics, immunotherapy, and transplant
techniques. The session also addresses lymphoedema management and lymphatic metastasis. Case-based learning will reinforce evidence-based care pathways.
Subtracks:
- Lymphoma Biology and Therapeutics
- Coagulopathies in Oncology Patients
- Haematopoietic Stem Cell Transplantation
- Minimal Residual Disease in Blood Cancers
- Immunotherapy in Haematologic Malignancies
- Lymphoedema and Lymphatic Metastasis
This session focuses
on the pharmacological basis of cancer therapy,
including mechanisms of drug action, pharmacokinetics, and toxicity profiles.
Experts will discuss drug resistance, combination regimens, and
pharmacogenomics in oncology. Emerging agents
like antibody-drug conjugates (ADCs) and targeted kinase inhibitors will be
featured. Case discussions will highlight the optimisation of dosing and
therapeutic drug monitoring to improve clinical outcomes.
Subtracks:
- Mechanisms of Action of Cancer Therapeutics
- Pharmacogenomics in Oncology Drug Selection
- Drug-Drug Interactions and Toxicity Management
- Antibody-Drug Conjugates and Biologic Therapies
- Therapeutic Drug Monitoring in Oncology
A forward-looking
session addressing the integration of artificial intelligence, machine
learning, and digital health technologies in oncology.
Topics include AI-powered imaging, predictive analytics, digital pathology,
and patient monitoring platforms.
Experts will discuss
ethical, regulatory, and data privacy concerns while highlighting real-world
applications of digital tools in diagnosis, treatment, and clinical
decision-making. This session aims to demystify AI and prepare oncologists for
the future of data-driven cancer care.
Subtracks:
- AI in Diagnostic Radiology and Pathology
- Predictive Analytics for Patient Outcomes
- Digital Twins and Virtual Patient Simulations
- Wearable and Remote Monitoring in Cancer Care
- Ethical AI Implementation in Oncology
- AI in Clinical Trial Design and Recruitment
Dedicated to
addressing the unique biological, clinical, and psychosocial aspects of
paediatric and rare cancers. This session will
discuss molecular subtypes, genetic
syndromes, and treatment-related challenges specific to these patient
populations.
Emphasis will be
placed on long-term survivorship, fertility preservation, and late effects of
therapy. Experts will also explore research networks and collaborative initiatives
essential for advancing care in these often-overlooked areas.
Subtracks:
- Molecular Drivers in Paediatric Tumours
- Rare Adult Cancers: Diagnosis and Management
- Long-Term Survivorship and Late Effects
- Fertility Preservation in Young Cancer Patients
- Rare Tumour Registries and Research Networks
- Paediatric CAR-T and Immunotherapy
This session focuses
on improving quality of life for cancer patients through comprehensive symptom
management, psychosocial support, and integrative care models. Experts will
present approaches for addressing emotional, spiritual, and family needs during
the cancer
journey. Palliative care
integration into active treatment plans and survivorship care will also be explored.
Subtracks:
- Pain and Symptom Management in Cancer
- Psychosocial Oncology and Patient Counselling
- Nutritional and Supportive Interventions
- End-of-Life Care and Decision-Making
- Integrative and Complementary Therapies
- Palliative Care in Paediatric and Geriatric Oncology
This session
highlights recent discoveries in cancer genomics, from driver mutations to tumour
mutational burden and neoantigen prediction. Experts will discuss multi-omics
approaches, epigenomics, and liquid
biopsy applications. The session aims
to translate genetic discoveries into actionable therapeutic strategies and
personalised treatment plans. It will also explore the future of precision oncology driven by real-time
genomic data.
Subtracks:
- Tumour Genomic Profiling and Biomarker Discovery
- Multi-Omics Approaches in Cancer Research
- Liquid Biopsy for Real-Time Tumour Monitoring
- Neoantigen Prediction for Personalised Immunotherapy
- Cancer Epigenomics and Methylation Markers
- AI in Genomic Data Interpretation
An essential session
exploring the design, conduct, and analysis of oncology
clinical trials. Discussions will address challenges in trial recruitment,
adaptive trial designs, and real-world data integration.
Experts will share
updates on pivotal oncology
trials and regulatory landscapes. Emphasis will be placed on patient safety,
ethical considerations, and strategies to improve diversity in trial
participation.
Subtracks:
- Adaptive and Basket Trial Designs
- Real-World Data in Oncology Research
- Ethical and Regulatory Aspects of Trials
- Patient-Reported Outcomes in Clinical Trials
- Challenges in Rare Cancer Trials
- Digital Tools for Trial Management and Recruitment
- Oncology Drug Discovery & Development
- Preventive Oncology and Risk Reduction
- Nutrition, Lifestyle & Cancer Care
- Global Perspectives in Oncology
- Next-Generation Oncology: Future Trends & Technologies
- Nervous System Tumours and Management
- Reproductive System Cancers
- Digestive System Malignancies
- Respiratory System Oncology
- Urinary System Tumours
- Musculoskeletal Cancers
- Prostate & Genitourinary Cancers
- Skin and Melanoma Research
- Endocrine Tumours & Thyroid Oncology